Bengaluru: The ‘warm’ vaccine formulation developed by scientists at IISC along with the biotech company MyNVAX is effective against all variants of the current SARS-COV-2 concern, independent evaluation of the formulation carried out by CSIRO, Australia has shown.
CSIRO, who did an animal test for the Oxford-Covishield vaccine candidate last year, found that the ‘warm’ vaccine helped produce antibodies that neutralized all the current variants of the Coronavirus novel.
This finding was published on Thursday in the Journal of the ACS Peer-Review Infectious Disease.
This will open the way for the clinical development of vaccines, which lead to human trials.
This study was led by Prof.
Raghavan Varadarajan from IISC.
TOI first reported about vaccines in November 2020.
Like paper, the researchers have shown a formulation of triggering strong immune responses in mice, protected hamster from viruses, and remains stable at 37 ° C for a month and at up to 90 minutes Until the ‘warm vaccine’ tag.
Most vaccines currently used require effective cooling – Oxford-astrazeneca must be stored at temperatures between 2 and 8 ° C; Pfizer requires special cold storage at -70 ° C.
IISC-mynvax vaccine has been designed by genetically engineering a s-protein domain, called receptor binding domain (RBD), from the SARS-COV-2 virus.
This domain attaches to ACE2 receptors on the surface of the target cells in the human respiratory tract that allows viruses to enter the body and cause infection.
S-protein viruses are around 1,300 long aminoacids, but vaccines only focus on 200 amino acid strings.
The next human trial, Varadarajan said they had submitted a request to the government for grants / funds for the human trial phase-i / II and phase III in India.
“We will need at least Rs 30 Crore for trials, and all I can be said at this time is that the funds have been implemented,” Varadarajan Toi said, adding that the results of the direct viral test by CSIRO were very encouraging.
He said CSIRO played an important role.
“CSIRO scientists in the center of the Australian Disease in Geelong contributed to the study by assessing vaccinated rats (blood samples) for efficacy of the main variants of Coronavirus, including Delta variants currently spread globally including in Sydney,” CSIRO said in a statement with TOI , Prof SS Vasan, Covid-19 CSIRO project leader and co-author, said vaccinated rats showed a strong response to all live viral variants.
“Our data shows that all formulations are tested to produce antibodies that are able to neutralize alpha, beta, gamma and delta variants that are consistent and effective,” he said.
Vasan told Tii in an exclusive telephone interview: “CSIRO will continue to work with IISC to develop the therapeutic application that will complement the vaccination strategy.
The lack of safe, effective and affordable therapy that specifically targets this virus is an urgent and unmet need.”